

By: Representatives Willis, Paden, Reynolds

To: Drug Policy

HOUSE BILL NO. 1547
(As Passed the House)

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,
2 TO REVISE SCHEDULE I OF THE CONTROLLED SUBSTANCES ACT TO INCLUDE
3 CERTAIN SYNTHETIC CANNABINOIDS, FENTANYLS AND FENTANYL-LIKE
4 SUBSTANCES THAT HAVE NO ACCEPTED MEDICAL USE, AND TO EXCLUDE HEMP
5 FROM CONTROL UNDER SCHEDULE I; TO AMEND SECTION 41-29-115,
6 MISSISSIPPI CODE OF 1972, TO AMEND SCHEDULE II TO EXCLUDE
7 NALDEMEDINE; TO AMEND SECTION 41-29-121, MISSISSIPPI CODE OF 1972,
8 TO REVISE SCHEDULE V TO INCLUDE A CANNABINOID THAT HAS BEEN
9 APPROVED AS A LEGEND DRUG BY THE FEDERAL FOOD AND DRUG
10 ADMINISTRATION; AND FOR RELATED PURPOSES.

11 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

12 **SECTION 1.** Section 41-29-113, Mississippi Code of 1972, is
13 amended as follows:

14 41-29-113. * * *

15 **SCHEDULE I**

16 (a) Schedule I consists of the drugs and other substances,
17 by whatever official name, common or usual name, chemical name, or
18 brand name designated, that is listed in this section.

19 (* * *b) **Opiates.** Unless specifically excepted or unless
20 listed in another schedule, any of the following opiates,
21 including their isomers, esters, ethers, salts and salts of
22 isomers, esters and ethers, * * * whenever the existence of these



23 isomers, esters, ethers and salts is possible within the specific
24 chemical designation:

25 (1) Acetyl-alpha-methylfentanyl;

26 (2) Acetyl Fentanyl

27 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;

28 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)
29 cyclohexylmethyl]benzamide);

30 (4) Acetylmethadol;

31 (5) Allylprodine;

32 (6) Alphacetylmethadol, except levo-alphacetylmethadol
33 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);

34 (7) Alphameprodine;

35 (8) Alphamethadol;

36 (9) Alpha-methylfentanyl;

37 (10) Alpha-methylthiofentanyl;

38 (11) Benzethidine;

39 (12) Betacetylmethadol;

40 (13) Beta-hydroxyfentanyl;

41 (14) Beta-hydroxy-3-methylfentanyl;

42 (15) Betameprodine;

43 (16) Betamethadol;

44 (17) Betaprodine;

45 (18) Butyrl fentanyl

46 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);

47 (19) Clonitazene;



48 (* * *20) Dextromoramide;

49 (* * *21) Diampromide;

50 (* * *22) Diethylthiambutene;

51 (* * *23) Difenoquin;

52 (* * *24) Dimenoxadol;

53 (* * *25) Dimepheptanol;

54 (* * *26) Dimethylthiambutene;

55 (* * *27) Dioxaphetyl butyrate;

56 (* * *28) Dipipanone;

57 (* * *29) Ethylmethylthiambutene;

58 (* * *30) Etonitazene;

59 (* * *31) Etoxadine;

60 (* * *32) Fentanyl-related substances, meaning any

61 substance not otherwise listed under another schedule and for

62 which no exemption or approval is in effect under Section 505 of

63 the Federal Food, Drug, and Cosmetic Act [21 USC 355] that is

64 structurally related to fentanyl by one or more of the following

65 modifications:

66 (A) Replacement of the phenyl portion of the

67 phenethyl group by any monocycle, whether or not further

68 substituted in or on the monocycle;

69 (B) Substitution in or on the phenethyl group with

70 alkyl, alkenyl, alkoxy, hydroxy, halo, haloalkyl, amino or nitro

71 groups;



72 (C) Substitution in or on the piperidine ring with
73 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl,
74 amino or nitro groups;

75 (D) Replacement of the aniline ring with any
76 aromatic monocycle whether or not further substituted in or on the
77 aromatic monocycle; and/or

78 (E) Replacement of the N-propionyl group by
79 another acyl group.

80 Fentanyl-related substances include, but are not limited to,
81 cyclopropyl fentanyl,

82 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

83 Furanyl-Fentanyl,

84 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

85 valeryl fentanyl,

86 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide);

87 para-fluorobutyryl fentanyl,

88 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

89 para-methoxybutyryl fentanyl,

90 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

91 para-chloroisobutyryl fentanyl,

92 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);

93 isobutyryl fentanyl,

94 (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);



95 cyclopentyl fentanyl,
96 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
97 and
98 ocfentanil,
99 (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetami
100 de);

- 101 (* * *33) Furethidine;
102 (* * *34) Hydroxypethidine;
103 (* * *35) Ketobemidone (including the optical and
104 geometric isomers);
105 (* * *36) Levomoramide;
106 (* * *37) Levophenacylmorphane;
107 (* * *38) 3-methylfentanyl;
108 (* * *39) 3-methylthiofentanyl;
109 (* * *40) Morpheridine;
110 (* * *41) MPPP

111 (1-methyl-4-phenyl-4-propionoxypiperidine);

112 * * *

113 (42)

114 *N*-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-*N*-phenylprop
115 ionamide, its isomers, esters, ethers, salts and salts of isomers,
116 esters and ethers (other names: beta-hydroxythiofentanyl);

117 (43) Noracymethadol;

118 (44) Norlevorphanol;

119 (45) Normethadone;



- 120 (46) Norpipanone;
121 (47) Para-fluorofentanyl;
122 (48) PEPAP
123 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
124 (49) Phenadoxone;
125 (50) Phenampromide;
126 (51) Phenomorphan;
127 (52) Phenoperidine;
128 (53) Piritramide;
129 (54) Proheptazine;
130 (55) Properidine;
131 (56) Propiram;
132 (57) Racemoramide;
133 (58) Thiofentanyl;
134 (59) Tilidine;
135 (60) Trimeperidine;
136 (61) U-47700,

137 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide.

138 (* * *c) **Opium derivatives.** Unless specifically excepted
139 or unless listed in another schedule, any of the following opium
140 derivatives, their salts, isomers and salts of isomers, * * *
141 whenever the existence of these salts, isomers and salts of
142 isomers is possible within the specific chemical designation:

- 143 (1) Acetorphine;
144 (2) Acetyldihydrocodeine;



- 145 (3) Benzylmorphine;
146 (4) Codeine methylbromide;
147 (5) Codeine-N-Oxide;
148 (6) Cyprenorphine;
149 (7) Desomorphine;
150 (8) Dihydromorphine;
151 (9) Drotebanol;
152 (10) Etorphine (except hydrochloride salt);
153 (11) Heroin;
154 (12) Hydromorphenol;
155 (13) Methyldesorphine;
156 (14) Methyldihydromorphine;
157 (15) Monoacetylmorphine;
158 (16) Morphine methylbromide;
159 (17) Morphine methylsulfonate;
160 (18) Morphine-N-Oxide;
161 (19) Myrophine;
162 (20) Nicocodeine;
163 (21) Nicomorphine;
164 (22) Normorphine;
165 (23) Pholcodine;
166 (24) Thebacon.
- 167 (* * *d) **Hallucinogenic substances.** Unless specifically
168 excepted or unless listed in another schedule, any material,
169 compound, mixture or preparation which contains any quantity of



170 the following substances, their salts, isomers (whether optical,
171 positional, or geometric) and salts of isomers, * * * whenever the
172 existence of these salts, isomers and salts of isomers is possible
173 within the specific chemical designation:

- 174 (1) Alpha-ethyltryptamine;
- 175 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 176 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 177 (4) 2,5-dimethoxyamphetamine;
- 178 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 179 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine
180 (2C-T-7);
- 181 (7) 4-methoxyamphetamine;
- 182 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 183 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 184 (10) 3,4-methylenedioxy amphetamine;
- 185 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 186 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known
187 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl
188 MDA, MDE, MDEA);
- 189 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also
190 known as N-hydroxy MDA, N-OHMDA, and
191 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);
- 192 (14) 3,4,5-trimethoxy amphetamine;
- 193 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 194 (16) Alpha-methyltryptamine (also known as AMT);



- 195 (17) Bufotenine;
- 196 (18) Diethyltryptamine;
- 197 (19) Dimethyltryptamine;
- 198 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 199 (21) Ibogaine;
- 200 (22) Lysergic acid diethylamide (LSD);
- 201 (23) (A) Marijuana (Cannabidiol contained in a legend
202 drug product approved by the Federal Food and Drug Administration
203 or obtained under Section 41-29-136 is exempt under Schedule I);
- 204 (B) Hashish;
- 205 (24) Mescaline;
- 206 (25) Parahexyl;
- 207 (26) Peyote;
- 208 (27) N-ethyl-3-piperidyl benzilate;
- 209 (28) N-methyl-3-piperidyl benzilate;
- 210 (29) Psilocybin;
- 211 (30) Psilocyn;
- 212 (31) Tetrahydrocannabinols, meaning
213 tetrahydrocannabinols contained in a plant of the genus Cannabis
214 (cannabis plant), as well as the synthetic equivalents of the
215 substances contained in the cannabis plant, or in the resinous
216 extractives of such plant, and/or synthetic substances,
217 derivatives, and their isomers with similar chemical structure and
218 pharmacological activity to those substances contained in the
219 plant such as the following:



- 220 (A) 1 cis or trans tetrahydrocannabinol;
221 (B) 6 cis or trans tetrahydrocannabinol;
222 (C) 3,4 cis or trans tetrahydrocannabinol.

223 (Since nomenclature of these substances is not
224 internationally standardized, compounds of these structures,
225 regardless of atomic positions, are covered.)

226 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)

227 However, the following products are exempted from control:

228 (i) THC-containing industrial products made
229 from cannabis stalks (e.g., paper, rope and clothing);

230 (ii) Processed cannabis plant materials used
231 for industrial purposes, such as fiber retted from cannabis stalks
232 for use in manufacturing textiles or rope;

233 (iii) Animal feed mixtures that contain
234 sterilized cannabis seeds and other ingredients (not derived from
235 the cannabis plant) in a formula designed, marketed and
236 distributed for nonhuman consumption;

237 (iv) Personal care products that contain oil
238 from sterilized cannabis seeds, such as shampoos, soaps, and body
239 lotions (if the products do not cause THC to enter the human
240 body); and

241 (v) Processed cannabis plant extract, oil or
242 resin with a minimum ratio of twenty-to-one cannabidiol to
243 tetrahydrocannabinol (20:1 cannabidiol:tetrahydrocannabinol), and
244 diluted so as to contain at least fifty (50) milligrams of



245 cannabidiol per milliliter, with not more than two and one-half
246 (2.5) milligrams of tetrahydrocannabinol per milliliter;

247 (vi) Hemp, meaning the plant Cannabis sativa
248 L. and any part of that plant, including the seeds thereof and all
249 derivatives, extracts, cannabinoids, isomers, acids, salts, and
250 salts of isomers, whether growing or not, with a delta-9
251 tetrahydrocannabinol (THC) concentration of not more than three-
252 tenths of one percent (0.3%) on a dry weight basis. This
253 subparagraph (vi) shall be effective from and after the date that
254 tetrahydrocannabinols in hemp as defined in this subparagraph have
255 been excluded from Schedule I of the federal Controlled Substances
256 Act.

257 (32) Phencyclidine;

258 (33) Ethylamine analog of phencyclidine (PCE);

259 (34) Pyrrolidine analog of phencyclidine (PHP, PCPy);

260 (35) Thiophene analog of phencyclidine;

261 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);

262 (37) 4-methylmethcathinone (mephedrone);

263 (38) 3,4-methylenedioxypropylvalerone (MDPV);

264 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);

265 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);

266 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);

267 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);

268 or 2,5-dimethoxy-4-iodophenethylamine;



269 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine
270 (2C-T-2);
271 (44)
272 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
273 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);
274 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
275 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine
276 (2C-P);
277 (48) 3,4-methylenedioxy-N-methylcathinone (methydone);
278 (49)
279 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
280 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
281 (50)
282 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
283 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
284 (51)
285 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or
286 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
287 Cimbi-5);
288 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,
289 4-benzodiazepin-2-one (also known as Phenazepam);
290 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,
291 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene
292 (also known as Etizolam);
293 (54) Salvia divinorum;



294 (55) Synthetic cannabinoids. Unless specifically
295 excepted or unless listed in another schedule, any material,
296 compound, mixture, or preparation which contains any quantity of a
297 synthetic cannabinoid found in any of the following chemical
298 groups, whether or not substituted to any extent, or any of those
299 groups which contain any synthetic cannabinoid salts, isomers, or
300 salts of isomers, whenever the existence of such salts, isomers,
301 or salts of isomers is possible within the specific chemical
302 designation, including all synthetic cannabinoid chemical
303 analogues in such groups:

304 (A) (6aR,10aR)-9-(hydroxymethyl)-6,
305 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]
306 chromen-1-ol (also known as HU-210 or
307 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

308 (B) Naphthoylindoles and naphthylmethylindoles,
309 being any compound structurally derived from 3-(1-naphthoyl)indole
310 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted
311 in the indole ring to any extent, or in the naphthyl ring to any
312 extent;

313 (C) Naphthoylpyrroles, being any compound
314 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not
315 substituted in the pyrrole ring to any extent, or in the naphthyl
316 ring to any extent;

317 (D) Naphthylmethylindenes, being any compound
318 structurally derived from 1-(1-naphthylmethyl)indene, whether or



319 not substituted in the indene ring to any extent or in the
320 naphthyl ring to any extent;

321 (E) Phenylacetylindoles, being any compound
322 structurally derived from 3-phenylacetylindole, whether or not
323 substituted in the indole ring to any extent or in the phenyl ring
324 to any extent;

325 (F) Cyclohexylphenols, being any compound
326 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether
327 or not substituted in the cyclohexyl ring to any extent or in the
328 phenolic ring to any extent;

329 (G) Benzoylindoles, whether or not substituted in
330 the indole ring to any extent or in the phenyl ring to any extent;

331 (H) Adamantoylindoles, whether or not substituted
332 in the indole ring to any extent or in the adamantoyl ring system
333 to any extent;

334 (I) Tetrahydro derivatives of cannabinal and
335 3-alkyl homologues of cannabinal or of its tetrahydro derivatives,
336 except where contained in cannabis or cannabis resin;

337 (J) 3-Cyclopropylmethanone indole or
338 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by
339 substitution at the nitrogen atom of the indole ring, whether or
340 not further substituted in the indole ring to any extent, whether
341 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl
342 rings to any extent;



343 (K) Quinolinyll ester indoles, being any compound
344 structurally derived from 1H-indole-3carboxylic acid-8-quinolinyll
345 ester, whether or not substituted in the indole ring to any extent
346 or the quinolone ring to any extent;

347 (L) 3-carboxamide-1H-indazoles, whether or not
348 substituted in the indazole ring to any extent and substituted to
349 any degree on the carboxamide nitrogen and
350 3-carboxamide-1H-indoles, whether or not substituted in the indole
351 ring to any extent and substituted to any degree on the
352 carboxamide nitrogen;

353 (M) Cycloalkanemethanone Indoles, whether or not
354 substituted at the nitrogen atom on the indole ring, whether or
355 not further substituted in the indole ring to any extent, whether
356 or not substituted on the cycloalkane ring to any extent.

357 (* * *e) **Depressants.** Unless specifically excepted or
358 unless listed in another schedule, any material, compound,
359 mixture, or preparation which contains any quantity of the
360 following substances having a depressant effect on the central
361 nervous system, including their salts, isomers, and salts of
362 isomers, whenever the existence of such salts, isomers, and salts
363 of isomers is possible within the specific chemical designation:

364 (1) Gamma-hydroxybutyric acid (other names include:
365 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic
366 acid; sodium oxybate; sodium oxybutyrate);

367 (2) Mecloqualone;



368 (3) Methaqualone.

369 (* * *f) **Stimulants.** Any material, compound, mixture or
370 preparation which contains any quantity of the following central
371 nervous system stimulants including optical salts, isomers and
372 salts of isomers unless specifically excepted or unless listed in
373 another schedule:

374 (1) Aminorex;

375 (2) N-benzylpiperazine (also known as BZP * * * and
376 1-benzylpiperazine);

377 (3) Cathinone;

378 (4) Fenethylamine;

379 (5) Methcathinone;

380 (6) 4-methylaminorex (also known as
381 2-amino-4-methyl-5-phenyl-2-oxazoline);

382 (7) N-ethylamphetamine;

383 (8) Any material, compound, mixture or preparation
384 which contains any quantity of N,N-dimethylamphetamine. (Other
385 names include: N,N,-alpha-trimethyl-benzeneethanamine * * * and
386 N,N-alpha-trimethylphenethylamine);

387 (9) **Synthetic cathinones.** (A) Unless listed in
388 another schedule, any compound other than bupropion that is
389 structurally derived from 2-Amino-1-phenyl-1-propanone by
390 modification in any of the following ways:

391 (i) By substitution in the phenyl ring to any
392 extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide



393 substituents, whether or not further substituted in the phenyl
394 ring by one or more other univalent substituents;

395 (ii) By substitution at the 3-position with
396 an alkyl substituent;

397 (iii) By substitution at the nitrogen atom
398 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom
399 in a cyclic structure.

400 (B) The compounds covered in this paragraph (9)
401 include, but are not limited to, any material compound, mixture or
402 preparation which contains any quantity of a synthetic cathinone
403 found in any of the following compounds, whether or not
404 substituted to any extent, or any of these compounds which contain
405 any synthetic cathinone, or salts, isomers, or salts of isomers,
406 whenever the existence of such salts, isomers or salts of isomers
407 is possible, unless specifically excepted or listed in another
408 schedule:

409 (i) 4-methyl-N-ethylcathinone ("4-MEC");

410 (ii) 4-methyl-alpha-pyrrolidinopropiophenone
411 ("4-MePPP");

412 (iii) Alpha-pyrrolidinopentiophenone
413 (" α -PVP");

414 (iv)
415 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone");

416 (v) 2-(methylamino)-1-phenylpentan-1-one
417 ("pentedrone");



418 (vi)
419 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one
420 ("pentylone");
421 (vii) 4-fluoro-N-methylcathinone ("4-FMC");
422 (viii) 3-fluoro-N-methylcathinone ("3-FMC");
423 (ix)
424 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one
425 ("naphyrone"); * * *
426 (x) Alpha-pyrrolidinobutiophenone
427 (" α -PBP") * * * ; and
428 (xi)
429 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one
430 (N-ethylpentylone, ephylone).

431 **SECTION 2.** Section 41-29-115, Mississippi Code of 1972, is
432 amended as follows:

433 41-29-115. (* * *a) The controlled substances listed in
434 this section, by whatever official name, common or usual name,
435 chemical name, or brand name designated, are included in Schedule
436 II.

437 SCHEDULE II

438 (* * *b) **Substances, vegetable origin or chemical**
439 **synthesis.** Unless specifically excepted or unless listed in other
440 schedules, any of the following substances, except those narcotic
441 drugs listed in other schedules, whether produced directly or
442 indirectly by extraction from substances of vegetable origin, or



443 independently by means of chemical synthesis, or by combination of
444 extraction and chemical synthesis:

445 (1) Opium and opiate, and any salt, compound,
446 derivative, or preparation of opium or opiate, excluding
447 apomorphine, thebaine-derived butorphanol, dextrorphan,
448 nalbuphine, naldemedine, nalmeferene, naloxegol, naloxone and
449 naltrexone, but including the following:

- 450 (i) Codeine;
- 451 (ii) Dihydroetorphine;
- 452 (iii) Ethylmorphine;
- 453 (iv) Etorphine hydrochloride;
- 454 (v) Granulated opium;
- 455 (vi) Hydrocodone, whether alone or in combination
456 with any material, compound, mixture or preparation;
- 457 (vii) Hydromorphone;
- 458 (viii) Metopon;
- 459 (ix) Morphine;
- 460 (x) Opium extracts;
- 461 (xi) Opium fluid extracts;
- 462 (xii) Oripavine;
- 463 (xiii) Oxycodone;
- 464 (xiv) Oxymorphone;
- 465 (xv) Powdered opium;
- 466 (xvi) Raw opium;
- 467 (xvii) Thebaine;



468 (xviii) Tincture of opium * * *;
469 (2) Any salt, compound, isomer, derivative, or
470 preparation thereof which is chemically equivalent or identical
471 with any of the substances referred to in paragraph (1), but not
472 including the isoquinoline alkaloids of opium;
473 (3) Opium poppy and poppy straw;
474 (4) Coca leaves and any salt, compound, derivative, or
475 preparation of cocaine or coca leaves, including cocaine and
476 ecgonine and any salt, compound, derivative, isomer, or
477 preparation thereof which is chemically equivalent or identical
478 with any of these substances, but not including:
479 (i) Decocainized coca leaves or extraction of coca
480 leaves, which extractions do not contain cocaine or ecgonine; or
481 (ii) Ioflupane;
482 (5) Concentrate of poppy straw (the crude extract of
483 poppy straw in either liquid, solid or powder form which contains
484 the phenanthrene alkaloids of the opium poppy).
485 (* * *c) **Opiates.** Any of the following opiates, including
486 their isomers, esters, ethers, salts, and salts of isomers,
487 whenever the existence of these isomers, esters, ethers and salts
488 is possible within the specified chemical designation, dextrorphan
489 and levopropoxyphene excepted:
490 (1) Alfentanil;
491 (2) Alphaprodine;
492 (3) Anileridine;



493 (4) Bezitramide;
494 (5) Bulk dextropropoxyphene (nondosage forms);
495 (6) Carfentanil;
496 (7) Dihydrocodeine;
497 (8) Diphenoxylate;
498 (9) Fentanyl;
499 (10) Isomethadone;
500 (11) Levo-alpha-acetylmethadol
501 (levo-alpha-acetylmethadol, levomethadyl acetate, LAAM);
502 (12) Levomethorphan;
503 (13) Levorphanol;
504 (14) Metazocine;
505 (15) Methadone;
506 (16) Methadone-intermediate,
507 4-cyano-2-dimethylamino-4,4-diphenyl butane;
508 (17) Moramide-intermediate,
509 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;
510 (18) Pethidine (meperidine);
511 (19) Pethidine-Intermediate-A,
512 4-cyano-1-methyl-4-phenylpiperidine;
513 (20) Pethidine-Intermediate-B,
514 ethyl-4-phenylpiperidine-4-carboxylate;
515 (21) Pethidine-Intermediate-C,
516 1-methyl-4-phenylpiperidine-4-carboxylic acid;
517 (22) Phenazocine;



- 518 (23) Piminodine;
- 519 (24) Racemethorphan;
- 520 (25) Racemorphan;
- 521 (26) Remifentanil;
- 522 (27) Sufentanil;
- 523 (28) Tapentadol;
- 524 (29) Thiafentanil,
- 525 4-(methoxycarbonyl)-4-(N-phenmethoxyacetamido)-1-[2-(thienyl)ethyl
- 526]piperidine.

527 (* * *d) **Stimulants.** Any material, compound, mixture, or
528 preparation which contains any quantity of the following
529 substances:

- 530 (1) Amphetamine, its salts, optical isomers, and salts
- 531 of its optical isomers;
- 532 (2) Phenmetrazine and its salts;
- 533 (3) Any substance which contains any quantity of
- 534 methamphetamine, including its salts, isomers, and salts of
- 535 isomers;
- 536 (4) Methylphenidate and its salts;
- 537 (5) Lisdexamfetamine, its salts, isomers and salts of
- 538 isomers.

539 (* * *e) **Depressants.** Unless specifically exempted or
540 unless listed in another schedule, any material, compound,
541 mixture, or preparation which contains any quantity of the
542 following substances:



- 543 (1) Amobarbital;
544 (2) Secobarbital;
545 (3) Pentobarbital;
546 (4) Glutethimide.

547 (* * *f) **Hallucinogenic substances.**

548 (1) Dronabinol oral solution
549 [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)];

550 (2) Nabilone [other names include:
551 (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-
552 hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one].

553 (* * *g) **Immediate precursors.** Unless specifically
554 excepted or unless listed in another schedule, any material,
555 compound, mixture, or preparation which contains any quantity of
556 the following substances:

557 (1) Amphetamine and methamphetamine immediate
558 precursor: Phenylacetone (other names include:
559 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
560 ketone);

561 (2) Phencyclidine immediate precursors:
562 (i) 1-phenylcyclohexylamine;
563 (ii) 1-piperidinocyclohexanecarbonitrile (PCC);

564 (3) Fentanyl immediate precursor:
565 4-anilino-N-phenethyl-4-piperidine (ANPP).

566 (* * *h) Any material, compound, mixture or preparation
567 which contains any quantity of a Schedule II controlled substance



568 and is listed as an exempt substance in 21 CFR, Section 1308.24 or
569 1308.32, shall be exempted from the provisions of the Uniform
570 Controlled Substances Law.

571 **SECTION 3.** Section 41-29-121, Mississippi Code of 1972, is
572 amended as follows:

573 41-29-121. * * *

574 **SCHEDULE V**

575 (a) Schedule V consists of the drugs and other substances,
576 by whatever official name, common or usual name, chemical name, or
577 brand name designated, listed in this section.

578 (b) Narcotic drugs. [Reserved]

579 (* * *c) **Narcotic drugs containing nonnarcotic active**
580 **medicinal ingredients.** Any compound, mixture or preparation
581 containing * * * any of the following narcotic drugs, or their
582 salts calculated as the free anhydrous base or alkaloid, in
583 limited quantities as set forth below, which also contains one or
584 more nonnarcotic active medicinal ingredients in sufficient
585 proportion to confer upon the compound, mixture or
586 preparation * * * valuable * * * medicinal qualities other than
587 those possessed by the narcotic drug alone:

588 (1) Not more than two hundred (200) milligrams of
589 codeine, or any of its salts, per one hundred (100) milliliters or
590 per one hundred (100) grams;



591 (2) Not more than one hundred (100) milligrams of
592 dihydrocodeine, or any of its salts, per one hundred (100)
593 milliliters or per one hundred (100) grams;

594 (3) Not more than one hundred (100) milligrams of
595 ethylmorphine, or any of its salts, per one hundred (100)
596 milliliters or per one hundred (100) grams;

597 (4) Not more than two and five-tenths (2.5) milligrams
598 of diphenoxylate and not less than twenty-five (25) micrograms of
599 atropine sulphate per dosage unit;

600 (5) Not more than one hundred (100) milligrams of opium
601 per one hundred (100) milliliters or per one hundred (100) grams;

602 (6) Not more than five-tenths (0.5) milligram of
603 difenoxin and not less than twenty-five (25) micrograms of
604 atropine sulfate per dosage unit.

605 (* * *d) **Stimulants.** Unless specifically excepted or
606 listed in another schedule, any material, compound, mixture or
607 preparation which contains any quantity of the following
608 substance, including its salts, isomers and salts of isomers:
609 Pyrovalerone.

610 (* * *e) **Depressants.** Unless specifically exempted or
611 excluded or unless listed in another schedule, any material,
612 compound, mixture or preparation which contains any quantity of
613 the following substances having a depressant effect on the central
614 nervous system, including their salts, isomers and salts of
615 isomers:



616 (1) Brivaracetam
617 ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also
618 referred to as BRV; UCB-34714; Briviact);

619 (2) Ezogabine [N-[2-amino-4-(4-
620 fluorobenzylamino)-phenyl]-carbamic acid ethyl ester];

621 (3) Lacosamide
622 [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];

623 (4) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic
624 acid].

625 (f) Approved cannabidiol drugs. A drug product in finished
626 dosage formulation that has been approved by the United States
627 Food and Drug Administration that contains cannabidiol
628 (2-R-3-methyl-6R-1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-
629 benzenediol) derived from cannabis and no more than 0.1 percent
630 (w/w) residual tetrahydrocannabinols.

631 (* * *g) Any material, compound, mixture or preparation
632 which contains any quantity of a Schedule V controlled substance
633 and is listed as an exempt substance in 21 CFR, Section 1308.22,
634 1308.24, 1308.26, 1308.32 or 1308.34, shall be exempted from the
635 provisions of the Uniform Controlled Substances Law.

636 **SECTION 4.** This act shall take effect and be in force from
637 and after its passage.

